RepligenRGEN +9.56%83 Interest Coverage is 3.10 as of Mar. 2026, which is 39% below its 10-year median of 5.10. GuruFocus rates RGEN with a GF Score™ of 83/100 and a GF Value™ of $175.89 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Repligen ranks worse than 87.82% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Repligen's
Operating Income
for the
three
months ended in Mar. 2026 was $17.3 Mil. Repligen's Interest Expense for the
three
months ended in Mar. 2026 was $-5.6 Mil.
Repligen's interest coverage for the quarter that ended in Mar. 2026 was 3.10.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Repligen's Interest Coverage or its related term are showing as below:
RGEN'
s Interest Coverage Range Over the Past 10 Years
Min: 1.93 Med: 5.1 Max: 168.62
Current: 2.39
RGEN's Interest Coverage is ranked worse than 87.82% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 15.71
vs RGEN: 2.39
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Repligen Interest Coverage Related Terms
Repligen Interest Coverage Historical Data
* Premium members only.
The historical data trend for Repligen's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
RGEN vs ATR, AVTR, TFX: Interest Coverage Comparison
For the Medical Instruments & Supplies subindustry, Repligen's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repligen Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Repligen's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repligen (RGEN) has a Interest Coverage of 3.10 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Repligen and its competitors. This is 39% below median its historical median of 5.10. Over the past decade, Repligen's Interest Coverage has ranged from 1.93 to 168.62. According to the industry distribution chart, Repligen ranks #411 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 87.8%.
Is Repligen's Interest Coverage too high?
Repligen's current Interest Coverage of 3.10 is 39% below median its 10-year median of 5.10. Over the past 10 years, this metric has ranged from a low of 1.93 to a high of 168.62. The Medical Devices & Instruments industry median Interest Coverage is 15.71. Repligen's value of 3.10 is 80.3% below this industry median. Based on the distribution chart, Repligen ranks #411 out of 468 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Repligen has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's Interest Coverage compare to ATR and AVTR?
According to the Medical Devices & Instruments industry distribution chart, Repligen ranks #411 out of 468 companies for Interest Coverage. This places Repligen in the lower half of its industry. The industry median Interest Coverage is 15.71. Repligen's value of 3.10 is 80.3% below this benchmark. Historically, Repligen's own Interest Coverage has ranged from 1.93 to 168.62 over the past decade. While the company's 10-year median is 5.10 vs. the industry median of 15.71, Repligen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 15.71, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Repligen's current Interest Coverage of 3.10 is 80.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Repligen and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Repligen's current Interest Coverage is 3.10, which is 39% below median its own 10-year median of 5.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $175.89, compared to a current price of $138.47 — trading 21.3% below its estimated fair value. The current Interest Coverage is 3.10, which is 39% below median its 10-year median of 5.10 and 80.3% below the Medical Devices & Instruments industry median of 15.71. Repligen's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Repligen (RGEN), the current Interest Coverage is 3.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Repligen (RGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Repligen stock appears to be undervalued.
The current stock price of $138.47 is trading 21.3% below its estimated GF Value™ of $175.89.
GuruFocus considers Repligen to be Modestly Undervalued.
Key valuation signals for RGEN:
Interest Coverage: 3.10 (39% below median its 10-year median of 5.10)
GF Value™: $175.89 vs. price of $138.47 (21.3% below fair value)
Industry Position: 80.3% below the Medical Devices & Instruments median (#411 of 468)
No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
83GF Score
Get the complete analysis for RGEN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEN has been successfully added to your 
